Model-Based Meta-Analysis of IL-17 A Inhibitors for Moderate-to-Severe Plaque Psoriasis: Establishing Exposure-Response Relationships to Inform Targeted Drug Development. (PubMed, Clin Rev Allergy Immunol) - Jan 16, 2026 - "This study aimed to establish an exposure-response model for IL-17 A inhibitors to predict the clinical efficacy of novel agents based on in vitro potency and pharmacokinetic parameters, guiding the development of new IL-17 A-targeting therapies. A systematic literature search was conducted in PubMed, Cochrane Library, and Embase to identify randomized controlled trials of three FDA-approved IL-17 A inhibitors: secukinumab, ixekizumab, and bimekizumab. External validation showed high predictive accuracy for xeligekimab. A reference table was also constructed to estimate required doses based on IC50 and desired therapeutic targets, facilitating rational dose selection. Based on existing pharmacokinetic and clinical efficacy data of IL-17 A inhibitors, this study successfully developed a streamlined and accurate exposure-response model, offers a practical tool for efficacy prediction and dose optimization in the..."
Clinical • Journal • Retrospective data • Review • Dermatology • Immunology • Psoriasis • IL17A
|
|
Ling Xu; Lujin Li; Qingshan Zheng; Xiaoya Chen; Yixiao Liu
|